Assessment of the fetoplacental complex and hemostasis system status in perinatal care of pregnant women with fetal congenital malformations

Authors

DOI:

https://doi.org/10.18370/2309-4117.2022.63.53-58

Keywords:

fetal congenital malformations, antenatal fetal death, placental dysfunction, Dopplerometry, hemostasis, low-frequency piezoelectric thromboelastography

Abstract

Research objective: to assess the morpho-functional status of the fetoplacental complex and hemostasis system in pregnant women with congenital malformations in the fetus to prevent antenatal fetal death and determine further tactics of management and delivery.
Materials and methods. The state of fetoplacental circulation was studied in 120 pregnant women with fetal congenital malformations in the third trimester by Doppler assessment of blood flow in the umbilical artery (UA) and middle cerebral artery (MCA) in the fetus, with resistance index, pulse index and maximum systolic and terminal diastolic velocities ratio. The functional activity of the hemostasis system was assessed by low-frequency piezoelectric thromboelastography. Morphological examination of the placenta was performed. The control group included 25 pregnant women without fetal congenital malformations.
Results. In case of Doppler flow disturbances in UA and combination of these disturbances with hypercoagulability, the probability of antenatal fetal death if there were congenital malformations ranged from 2–3 to 7–14 days (r = 0.51 and r = 0.55, respectively). A high risk of antenatal fetal death occurred with blood flow disorders in the UA and MCA (r = 0.70), as well as with blood flow disorders in the UA in combination with hypercoagulation and inhibition of fibrinolysis (r = 0.78). The highest risk of antenatal death occurred in case of impaired blood flow in the MCA with hypercoagulation and inhibition of fibrinolysis (r = +0.99).
An urgent delivery within a day is indicated when there are blood flow disorders in the UA or MCA, combined with hypercoagulation and inhibition of fibrinolysis. The respiratory distress syndrome is treated by administering a surfactant at gestational ages up to 34 weeks. Delivery within 2–3 days is indicated in case of impaired blood flow in the UA and hypercoagulation, this allows preventing of respiratory distress syndrome with corticosteroids if the gestational age is less than 34 weeks.
Conclusions. In pregnant women with fetal congenital malformations, significant disturbances in blood flow in the UA (increased resistance index and maximum systolic and final diastolic velocities ratio) and decreased pulse index in the MCA were revealed, which indicates intrauterine hypoxia and centralization of blood flow. The functional activity of the hemostasis system was characterized by an increase in the blood coagulation potential in the vascular-platelet, a coagulation unit, which was accompanied by morphological and functional changes in the placenta in response to hypoxia.
Implementation of the proposed algorithm for perinatal support of pregnant women with fetal congenital malformations and placental dysfunction helps to optimize pregnancy management and delivery, reduce perinatal morbidity and mortality.

Author Biographies

D.M. Shchurko, Odesa National Medical University, Odesa

PhD, assistant, Obstetrics and Gynecology Department

M.I. Shchurko, Odesa National Medical University, Odesa

PhD, associate professor, Obstetrics and Gynecology Department

N.M. Rozhkovska, Odesa National Medical University, Odesa

MD, professor, Obstetrics and Gynecology Department

S.P. Posokhova, Odesa National Medical University, Odesa

MD, professor, Obstetrics and Gynecology Department

V.O. Sytnikova, Odesa National Medical University, Odesa

MD, professor, Normal and Pathological Clinical Anatomy Department

References

  1. Zhabchenko, I.A., Pysareva, S.P., Shamaieva, O.V. “The results of scientific research the most significant factors complicated course of gestation in women of Ukraine.” The Health of Society 2.1 (2013): 43–8.
  2. Zaporozhan, V.N., Babii, I.L., Galych, S.R., et al. Congenital malformations. Odesa: ONMedU (2012): 320 p.
  3. Makarchuk, O.M., Kusa, O.M. “Reproductive health status in women at high risk of intrauterine infection.” Scientific digest of Association of Obstetricians and Gynecologists of Ukraine. Suppl (2012): 39–42..
  4. Sorokman, T.V., Pidvysotska, N.I., Hinhuliak, N.V. “Multifactor analysis of risk factors for congenital heart disease.” Child’s health 3.24 (2010): 1–4.
  5. Arbeille, P., Perrotin, F., Salihagic, A., et al. “Fetal Doppler Hypoxic index for the prediction of abnormal fetal heart rate at delivery in chronic fetal distress.” Eur J Obstet Gynecol Reprod Biol 121.2 (2005): 171–7. DOI: 10.1016/j.ejogrb.2004.11.032
  6. Benirchke, K., Kaufmann, P. Patology of the Human Placenta. New York: Springer (2010): 947 p.
  7. Berbets, A.M., Davydenko, I.S., Barbe, A.M., et al. “Melatonin 1A and 1B Receptors’ Expression Decreases in the Placenta of Women with Fetal Growth Restriction.” Reproductive Sciences 1 (2020): 8–16: DOI: 10.1007/s43032-020-00285-5
  8. Costa, M.A. “The endocrine function of human placenta: an overview.” Reproductive Bio Medicine Online 32 (2016): 14–43. DOI: 10.1016/j.rbmo.2015.10.005
  9. De Lange, N.M., Lance, M.D., de Groot, R., et al. “Obstetric hemorrhage and coagulation: an update. Thromboelastography, thromboelastometry, and conventional coagulation tests in the diagnosis and prediction of postpartum hemorrhage.” Obstet Gynecol Surv 67 (2012): 426–35. DOI: 10.1097/OGX.0b013e3182605861
  10. Ely, D.M., Driscoll, A.K. “Infant Mortality in the United States, 2017: Data From the Period Linked Birth/Infant Death File.” Natl Vital Stat Rep 68 (2019): 1–20.
  11. Figueras, F., Gratacos, E. “An integrated approach to fetal growth restriction.” Best Pract Res Clin Obstet Gynaecol 38 (2017): 48–58. DOI: 10.1016/j.bpobgyn.2016.10.006
  12. Ganzevoort, W., Mensing van Charante, N., et al. “How to monitor pregnancies complicated by fetal growth restriction and delivery below 32 weeks: a post-hoc sensitivity analysis of the TRUFFLE-study.” Ultrasound Obstet Gynecol 49 (2017): 769–77. DOI: 10.1002/uog.17433
  13. Ibeh, N., Okocha, C.E., Aneke, C.J., et al. “Normal pregnancy and coagulation profile: from the first through the third trimester.” Niger J Med 24 (2015): 54–7.
  14. Katz, D., Beilin, Y. “Disorders of coagulation in pregnancy.” Br J Anaesth 115.2 (2015): 1175–88.
  15. Levytska, K., Higgins, M., Keating, S., et al. “Placental pathology in relation to uterine artery doppler findings in pregnancies with severe intrauterine growth restriction and abnormal umbilical artery Doppler changes.” Am J Perinatol 34.5 (2017): 451–7. DOI: 10.1055/s-0036-1592347
  16. Morris, R.K., Selman, T.J., Verma, M. “Systematic reviw and meta-analysis of the test accuracy of ductus venosus Doppler to predict compromise of fetal/neonatal wellbeing in high risk pregnancies with placental insufficiency.” Eur J Obstet Gynecol Reprod Biol 152 (2015): 3–12. DOI: 10.1016/j.ejogrb.2010.04.017
  17. Muresan, D., Rotar, I.C., Stamatian, F. “The usefulness of fetal Doppler evaluation in early versus late onset intrauterine growth restriction. Review of the literature.” Med Ultrason 18.1 (2016): 103–9. DOI: 10.11152/mu.2013.2066.181
  18. Murphy, S.L., Mathews, T.J., Martin, J.A., et al. “Annual Summary of Vital Statistics: 2013–2014.” Pediatrics 139 (2017).
  19. Nardozza, L.M., Caetano, A.C., Zamarian, A.C., et al. “Fetal growth restriction: current knowledge.” Arch Gynecol Obstet 295.5 (2017): 1061–77. DOI: 10.1007/s00404-017-4341-9
  20. Ota, E., da Silva Lopes, K., Middleton, P., et al. “Antenatal interventions for preventing stillbirth, fetal loss and perinatal death: an overview of Cochrane systematic reviews (Meta-Analysis).” Cochrane Database Syst Rev 12.12 (2020): CD009599. DOI: 10.1002/14651858.CD009599.pub2
  21. Pérez-Calatayud, Á.A., Briones-Garduño, J.C., Rojas-Arellano, M. “Use of thromboelastography and thromboelastometry for the rational and opportune transfusion of hemoderivatives in obstetric hemorrhage.” Ginecol Obstet Mex 83.09 (2015).
  22. Sheppard, S.J., Khalil, R.A. “Risk factors and mediators of the vascular dysfunction associated with hypertension in pregnancy.” Cardiovasc Hematol Disord Drug Targets 10 (2015): 33–52. DOI: 10.2174/187152910790780096
  23. Shi, H., Enriquez, A., Rapadas, M., et al. “NAD Deficiency, Congenital Malformations, and Niacin Supplementation.” N Engl J Med 377 (2017): 544–52.
  24. Queensland Clinical Guidelines. Term small for gestation age baby (2016): 21 p.
  25. Tiulienieva, O., Davydenko, I., Tiulienieva, V., et al. “Histological criteria of maturity of the uterine-placental area of manure.” Journal of Education, Health and Sport 11.05 (2021): 275–80.

Downloads

Published

2022-05-27

How to Cite

Shchurko, D., Shchurko, M., Rozhkovska, N., Posokhova, S., & Sytnikova, V. (2022). Assessment of the fetoplacental complex and hemostasis system status in perinatal care of pregnant women with fetal congenital malformations. REPRODUCTIVE ENDOCRINOLOGY, (63-64), 53–58. https://doi.org/10.18370/2309-4117.2022.63.53-58

Issue

No. 63-64 (2022)

Section

Treatment of infertility and pregnancy

License

Copyright (c) 2022 Д.М. Щурко, M.І. Щурко, Н.М. Рожковська, С.П. Посохова, В.О. Ситнікова

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.